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Abstract
Background: Mammographic density decreases and involution of breast tissue increases with age; both are
thought to be risk factors for breast cancer. The current study investigated the relationship between involution or
hormone treatment (HT) and breast density among multiethnic patients with breast cancer in Hawaii.
Methods: Patients with breast cancer cases were recruited from a nested case-control study within the Multiethnic
Cohort. HT use was self-reported at cohort entry and at the time of the density study. Mammographic density and
involution in adjacent non-tumor breast tissue were assessed using established methods. Linear regression was
applied to evaluate the correlation between involution and four density measures and to compute adjusted means
by involution status while adjusting for confounders.
Results: In the 173 patients with breast cancer, mean percent breast density was 41.2% in mammograms taken
approximately 1 year before diagnosis. The respective proportions of women with no, partial, and complete
involution were 18.5, 51.4, and 30.1%, respectively and the adjusted density values for these categories were 32.5,
39.2, and 40.2% (p = 0.15). In contrast, the size of the dense area was significantly associated with involution (p = 0.
001); the values ranged from 29.7 cm2 for no involution to 48.0 cm2 for complete involution. The size of the total
breast area but not of the non-dense areas was also larger with progressive involution. Percent density and dense
area were significantly higher in women with combined HT use.
Conclusions: Contrary to previous reports, greater lobular involution was not related to lower mammographic
density but to higher dense area. Possibly, percent density during the involution process depends on the timing of
mammographic density assessment, as epithelial tissue is first replaced with radiographically dense stromal tissue
and only later with fat.
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Background
The human breast has 15–20 lobes, each with many lob-
ules containing acini, the secretory structures of the breast
[1]. Lobules are surrounded by varying amounts of stroma
and fat. With age, the progressive replacement of glandu-
lar elements with collagen and fat is accompanied by
histologic loss of epithelial cells available for malignant
transformation and results in lobules characterized by aci-
nar epithelia and fibrosis of the intralobular stroma [2, 3].
Delayed involution [2], i.e., variations in the rate or extent
of decrease in the number and size of breast lobules with
aging contributes to breast cancer risk [4]. For example,
women with only type I lobules, i.e., complete involution,
had a lower breast cancer risk than women with type II
and type III lobules [2, 5].
Involution of the glandular structures of the breast may
be reflected in mammographic density, an independent
predictor of breast cancer. Women with extensive breast
density (>75%) have fourfold to six-fold higher risk than
women with low (<5%) density [6, 7]. Tissues with low
and high mammographic density differ in their proportion
of stroma, collagen, epithelium, and fat [8], but dense
areas represent epithelial and stromal tissues [9]. Bio-
logical processes underlying breast involution and density
may share common hormonal influences, such as hor-
mone therapy (HT), which affects breast cancer risk, invo-
lution, and mammographic density [10, 11].
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In women attending the Mayo clinic with benign breast
disease, the mean percent density values by none, partial,
and complete involution status were 22, 22, and 17%, re-
spectively, after adjustment for known risk factors [1]. In a
case-control study within the same population [6], the
combination of no involution plus dense breasts was
related to fourfold higher risk of breast cancer. A later
report on women with benign biopsies also described a
significant inverse association between involution and
percent density but not absolute density, particularly
among premenopausal women [12]. In the current
study, we analyzed the association between breast density
and involution as the primary objective, but also examined
the well-known association between HT and mammo-
graphic density among women in Hawaii.
Methods
Study population
The current pathologic investigation [13] is based on
Hawaii participants of the Multiethnic Cohort (MEC),
who took part in a nested case-control (NCC) study of
mammographic density and breast cancer risk [14]. The
MEC was established in 1993–1996 by mailing a self-
administered, 26-page questionnaire asking about demo-
graphic, anthropometric, and medical factors to men
and women ages 45–75 years residing in Hawaii and
California [15]. Additional information on HT, meno-
pausal status, and mammograms was obtained when
women enrolled in the NCC study.
The MEC is linked annually to the statewide Hawaii
Tumor Registry (HTR) to identify incident cancer cases.
Invitations for the pathology study were mailed to 430 of
the 607 women in the NCC study, for whom tumor
blocks were available through the HTR. Of the 279
women with breast tumor tissue represented on micro-
arrays [16], blocks with sufficient non-tumor tissue to
assess breast involution were only available for 173
women, as many of the biopsy specimens were small
and did not contain enough benign tissue to evaluate in-
volution. The Institutional Review Board at the Univer-
sity of Hawaii approved all study protocols; all women
signed informed consent to be part of the NCC and the
pathology investigation.
Mammographic density assessment
Mammographic images of study participants from clinics
throughout the State of Hawaii were retrieved and digitized
using a Kodak LS 85 Film Digitizer (Kodak, Rochester, NY,
USA) with a pixel size of 260 μm [14]. For the pathology
study, the results of craniocaudal-projection images ob-
tained closest to, but before, the date of diagnosis were se-
lected [13]. Using the Cumulus software developed at the
University of Toronto, Canada [17], the scanned images for
both breasts were assessed for density (Fig. 1) by one reader
(GM) who was blinded to case status and time sequence of
mammograms [14]. Percent density was computed as the
dense area divided by the total breast area and non-dense
area as the difference between the total breast and the
dense area. The intraclass correlation coefficients derived
from duplicate readings were 0.96 for the size of the dense
area and 0.97 for percent density [14].
Pathologic assessment of lobular involution
Pathologic blocks were retrieved through the tissue re-
pository of the HTR. H&E slides (mean = 2.6 per
woman) of normal (non-tumor) tissue adjacent to but
not immediately bordering the tumor were prepared.
The extent of breast tissue lobular involution (Fig. 1) in
breast tissue was evaluated by a pathologist (DH) who
was blinded to mammographic, clinical, and risk factor
data. The extent of lobular involution was based on
morphologic assessment of terminal duct lobular units
(TDLUs) classified into one of three categories [18]: no
involution (0% involuted), partial (1–74%), or complete
(≥75%). TDLUs with abnormal features (e.g. dilation of
acini, hyperplasia, metaplasia, or calcifications) were ex-
cluded from evaluation.
Statistical analysis
The statistical analysis was performed using the SAS
statistical software (SAS Institute Inc., Cary, NC, USA).
We computed frequencies and means for variables of
interest by involution status. Multiple linear regression
was applied to evaluate the relationship between involu-
tion and mammographic measures (percent density,
dense area, non-dense area, and total area) and to com-
pute adjusted means by the category of involution and
HT. Separate models for premenopausal and pos-
tmenopausal women were analyzed. Trend tests were
performed using the indicator variables for involution
status as a continuous variable. All models were adjusted
for covariates known to be associated with breast
density: age at mammogram, body mass index (BMI)
(<25, 25 to <30, ≥30 kg/m2), ethnicity (Caucasian, Native
Hawaiian, Japanese, other), parity (0, 1–2, 3+), meno-
pausal status, and HT use (none, estrogen only, estrogen
plus progesterone).
Results
The mean age at breast cancer diagnosis in the 173
women in the involution study (62% of the original study
population) was 59.7 ± 8.0 years as compared to 61.4 ±
8.7 years in the 279 participants in the original study
(Table 1). The distributions of ethnicity, BMI, and repro-
ductive factors, HT use, and cancer stage) were very
similar in the subset and the original study, but percent
density and dense area were slightly higher and non-
dense and total area lower than in the entire study
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population, in mammograms taken 1.1 ± 1.1 years before
diagnosis. Approximately half of the women (51.4%)
were classified as having partial involution, followed by
30.1% and 18.5% with complete and no involution, re-
spectively. The majority of women were postmenopausal
(69.4%). The population represented Caucasians (33.5%),
Japanese (46.2%), Native Hawaiians (11.0%), and other
ethnic groups (9.3%). Past or present HT use was re-
ported by 65.9% of all women. The cancer stage in the
majority of women was localized (60.7%), followed by in
situ (22.5%) and advanced (12.1%). Involution status dif-
fered significantly by age at diagnosis (p = 0.01) with low
involution among women under 50 years of age and
higher proportions in women 60 years and older
(Table 1). Partial and complete involution did not differ
significantly by previous HT (p = 0.58).
The mean breast density in all women was 41.2%; the
unadjusted values (Fig. 2) were similar for no, partial,
and complete involution (38.8, 42.8, and 40.0%, re-
spectively; p = 0.96). The difference across categories in-
creased after adjustment for confounders (32.5, 39.2, and
40.2%, respectively) but was not significant (p = 0.15). In
contrast, the size of the dense area differed significantly in
the unadjusted (p = 0.03) and adjusted models (p = 0.001)
with the highest value for women with complete involu-
tion (48.0 cm2) and the lowest (29.7 cm2) for those with
no involution. The non-dense area varied little (80.9, 77.5,
and 83.4 cm2, respectively; p = 0.72), whereas the total
breast area was significantly higher with more advanced
involution before (p = 0.009) and after adjustment (110.6,
118.4, 131.4 cm2, respectively, p = 0.02). Interaction terms
and stratified analyses did not indicate any differences by
menopausal status. Involution was not associated with
percent density in premenopausal or postmenopausal
women (p = 0.27 and 0.42, respectively), whereas the
dense area remained higher with progressive involution
(p = 0.04 and 0.02, respectively).
HT was significantly associated with several mammo-
graphic measures (Fig. 2). Percent density (30.7, 36.5,
and 44.6%; p = 0.01) and dense area (31.2, 37.7, 49.7 cm2;
p = 0.002) were higher in women with combined HT
use, but the non-dense and the total area was not associ-
ated with HT use.
Discussion
As in previous reports, age was a strong predictor of in-
volution among MEC participants in Hawaii; complete
involution is uncommon before the age of 50 years and
Fig. 1 Examples of involution status (0%, 1–74%, and ≥75%) and mammographic density
Maskarinec et al. Breast Cancer Research  (2016) 18:128 Page 3 of 7
increases to as much as 50% in women aged 60 years
and older [2, 9]. In the current analysis, women with
more advanced involution had greater dense and total
breast areas, whereas percent density and non-dense
area were not related to involution. This lack of an
association between involution and percent density is in
contrast to a Mayo study, in which there was lower
percent density with more advanced involution [1], and
an investigation of benign diagnostic biopsies reporting
a direct association between percent mammographic





No involution Partial involution Complete involution P valueb
(0%) (1–74%) (≥75%)
Sample size (%) 279 173 32 (18.5) 89 (51.4) 52 (30.1) N/A
Age at diagnosis
< 50 years 24 (8.6) 15 (8.7) 7 (21.9) 7 (7.9) 1 (1.9) 0.01
50 to <55 years 56 (20.1) 42 (24.3) 6 (18.8) 25 (28.1) 11 (21.2)
55 to <60 years 55 (19.7) 40 (23.1) 12 (37.5) 18 (20.2) 10 (19.2)
60 to <65 years 44 (14.3) 31 (17.9) 3 (9.4) 17 (19.1) 11 (21.2)
65+ years 104 (37.3) 45 (26.0) 4 (12.5) 22 (24.7) 19 (36.5)
Menopausal status (%)
Premenopausal 76 (27.2) 53 (30.6) 12 (37.5) 28 (31.5) 13 (25.0) 0.47
Postmenopausal 203 (72.8) 120 (69.4) 20 (62.5) 61 (68.5) 39 (75.0)
Ethnicity (%)
Caucasian 97 (34.8) 58 (33.5) 7 (21.9) 35 (39.3) 16 (30.8) 0.39
Japanese American 121 (43.4) 80 (46.2) 16 (50.0) 39 (43.8) 25 (48.1)
Native Hawaiian 36 (12.9) 19 (11.0) 6 (18.8) 6 (6.7) 7 (13.5)
Other 25 (8.9) 16 (9.3) 3 (9.4) 9 (7.7) 4 (7.7)
Parity
Nulliparous 47 (16.9) 25 (14.4) 6 (18.8) 8 (9.0) 11 (21.2) 0.16
1–2 children 110 (39.4) 69 (39.9) 15(46.9) 38 (42.7) 16 (30.8)
3 or more children 122 (43.7) 79 (45.7) 11 (34.4) 43 (48.3) 25 (46.1)
Hormone use (%)
Never 102 (36.5) 59 (34.1) 9 (28.1) 28 (31.5) 22 (42.3) 0.58
Estrogen 97 (34.8) 62 (35.8) 11 (34.4) 34 (38.2) 17 (32.7)
Estrogen/progesterone 80 (28.7) 52 (30.1) 12 (37.5) 27 (30.3) 13 (25.0)
Body mass index
< 25 kg/m2 167 (59.9) 104 (60.1) 18 (56.3) 56 (62.9) 30 (57.7) 0.60
25 to <30 kg/m2 81 (29.0) 54 (31.2) 12 (37.5) 27 (30.3) 17 (28.9)
30+ kg/m2 31 (11.1) 15 (8.7) 2 (6.3) 6 (6.7) 7 (13.5)
Tumor stage (%)
In situ 61 (21.9) 39 (22.6) 10 (31.3) 18 (20.2) 11 (21.2) 0.60
Localized 169 (60.6) 105 (60.7) 20 (62.5) 53 (59.6) 32 (61.5)
Advanced 37 (13.2) 21 (12.1) 2 (6.3) 13 (14.6) 6 (11.5)
Missing 12 (4.3) 8 (4.6) 0 (0.0) 5 (5.6) 3 (5.8)
Mammographic measures
Percent density 37.6 41.2 38.8 42.8 40.0 0.96
Dense area (cm2) 37.8 40.8 32.6 41.6 44.7 0.04
Non-dense area (cm2) 77.5 67.8 63.9 64.9 75.1 0.24
Total area (cm2) 115.3 108.6 96.5 106.4 119.5 0.02
aNumbers and percentages except for mammographic measures; percentages may not add up to 100 due to rounding
bBased on the chi-square test for categorical variables and general linear models for continuous variables
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density and TDLU count around the biopsy site, but pri-
marily in premenopausal women [12]. There was no as-
sociation between involution and absolute dense area/
volume in either of these reports. Unlike in the study by
Gierach et al. [12], the associations in the current ana-
lysis did not differ by menopausal status. In a study from
Vermont that examined the relationship between circu-
lating IGF-1 and involution or breast density, the posi-
tive correlation between TDLU counts and percent
density was not significant after adjustment for con-
founders [19].
Our finding of larger dense areas on mammograms of
more involuted breasts suggests that women with a
larger degree of involution may not have more fatty tis-
sue but rather a higher proportion of stromal tissue.
Thus, the mammographic images appear radiographic-
ally dense despite being poor in epithelial cells. In the
two previous reports [1, 12] of inverse associations be-
tween involution and percent density, but not with
dense area, the authors argued that lobules were not re-
placed exclusively by stroma but by a combination of
stroma and fat [1]. Possible reasons for the discrepant
results include the small sample size of 173 women, the
ethnic diversity, and the fact that all women were diag-
nosed with breast cancer. As the pathology specimens
were obtained from the area surrounding the tumor in
Fig. 2 Mammographic measure by involution status and hormone treatment. Means and p values were obtained using general linear models
and were adjusted for ethnicity, age, body mass index, menopausal status, and parity. E estrogen, P progesterone
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previous studies, they likely represented higher-risk tis-
sue than breast tissue identified as benign on biopsy ob-
tained prior to cancer diagnosis [1, 12].
Our findings confirm the strong association between
mammographic density and HT, especially estrogen and
progesterone combined [20], but the degree of involu-
tion was only weakly associated with HT in the current
analysis, although previous reports describe less involu-
tion in women taking HT and suggest that estrogens
play a role in involution and breast density [1]. It has
also been reported that postmenopausal women with
higher estradiol levels were more likely to have higher
TDLU counts [21]. While exogenous intake of estrogen
may stimulate growth in breast tissue and provide more
epithelial cells at risk of mutation, estrogen could also
delay the age-related involution of the lobules through
mechanisms that are yet to be defined [4]. The import-
ance of breast tissue structure was emphasized by a
case-control study within the Nurses’ Health study [5];
women with predominant type I and no type III lobules
had a 30% lower risk of breast cancer than those with
no type I lobules or mixed lobule types.
Strengths of the current study include the ethnic di-
versity with a wide range of mammographic density
values [14], the availability of many covariates, and the
quantitative breast density assessment providing dense
and non-dense area measures. However, the major weak-
ness is that all participants of the current study were di-
agnosed with breast cancer, thus, their breast tissue may
have been less involuted than tissue in women with be-
nign biopsies [1, 12] and may be responsible for the ob-
served positive associations. Other limitations include the
lack of slides for more than 100 women who participated
in the original study [16]. Although the distribution by
stage of diagnosis for the current study samples was simi-
lar to the original 279 study participants (Table 1), the
study population was slightly younger and the total breast
area was larger and the dense area smaller, resulting in
lower percent density (Table 1). As different approaches in
assessing involution have been applied, i.e., TDLU counts,
TDLU span, and acini counts/TDLU, it is not clear how
comparable our findings, based on a simple method, are
to previous reports. Nevertheless, all measures started
declining significantly in the third decade of age and all
metrics were statistically significantly lower among post-
menopausal women [18].
Conclusions
Contrary to previous reports [1, 12], greater lobular in-
volution was not related to lower mammographic dens-
ity but to higher dense area, in the current analysis of a
small number of breast cancer cases. It is possible that
percent density during the involution process depends
on the timing of mammographic density assessment, as
epithelial tissue is first replaced with radiographically
dense stromal tissue and only later with fat. Hence, per-
cent density in breast tissue undergoing involution may
depend on the timing within the involution process when
mammographic density was assessed. In addition to epi-
thelial cell death and remodeling, the presence of immune
cells and inflammatory response to remove debris may in-
fluence the appearance of the breast [3, 22]. Based on the
limited evidence, it is tempting to consider involution and
mammographic density as intermediate endpoints in
breast carcinogenesis [6], as both measures are related to
aging, as collagen, glandular area, and nuclear area [10],
and rely on visual assessments of tissue architecture, one
at the microscopic and the other at the macroscopic level.
However, at this time we do not have information on the
average rate of involution, the timing of the transitional
process, and possible differences in the process among
women with and without breast cancer.
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